Analyst Ratings for Nektar Therapeutics and Peers in March 2018
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.